Cargando…

Reflections on the US FDA's Warning on Direct-to-Consumer Genetic Testing

In November 2013, the US Food and Drug Administration (FDA) sent a warning letter to 23andMe, Inc. and ordered the company to discontinue marketing of the 23andMe Personal Genome Service (PGS) until it receives FDA marketing authorization for the device. The FDA considers the PGS as an unclassified...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yim, Seon-Hee, Chung, Yeun-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korea Genome Organization 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4330248/ https://www.ncbi.nlm.nih.gov/pubmed/25705152 http://dx.doi.org/10.5808/GI.2014.12.4.151

Ejemplares similares

The Effects of the FDA Warning on the Use of Droperidol by U.S. Emergency Physicians
por: Richards, John R., et al.
Publicado: (2003)

Introduction to International Ethical Standards Related to Genetics and Genomics
por: Yim, Seon-Hee, et al.
Publicado: (2013)

The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin
por: Anand, Kanika, et al.
Publicado: (2017)

Direct-to-consumer genetic testing
por: Kim, Jong-Won
Publicado: (2019)

Direct-to-consumer genetic testing
por: Horton, Rachel, et al.
Publicado: (2019)

Molecular Epidemiology of Female Lung Cancer
por: Yim, Seon-Hee, et al.
Publicado: (2011)

An Overview of Biomarkers and Molecular Signatures in HCC
por: Yim, Seon-Hee, et al.
Publicado: (2010)

Institutional response to FDA warning on aprotinin and impact on outcomes
por: Swaminathan, M, et al.
Publicado: (2009)

The FDA authorization of direct-to-consumer genetic testing for three BRCA1/2 pathogenic variants: a twitter analysis of the public’s response
por: Roberts, Megan C, et al.
Publicado: (2019)

855. Impact of FDA Black Box Warning on Fluoroquinolone and Alternative Antibiotic Use in Southeastern US Hospitals
por: Yarrington, Michael, et al.
Publicado: (2018)

Testing front-of-package warnings to discourage red meat consumption: a randomized experiment with US meat consumers
por: Taillie, Lindsey Smith, et al.
Publicado: (2021)

Polygenic Scores in the Direct-to-Consumer Setting: Challenges and Opportunities for a New Era in Consumer Genetic Testing
por: Park, Jin K., et al.
Publicado: (2023)

The ethics and regulation of direct-to-consumer genetic testing
por: Boddington, Paula
Publicado: (2009)

Direct-to-consumer genetic testing: advantages and pitfalls
por: Oh, Bermseok
Publicado: (2019)

Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies
por: Hagan, John B., et al.
Publicado: (2021)

Clinical implications of copy number variations in autoimmune disorders
por: Yim, Seon-Hee, et al.
Publicado: (2015)

Direct-to-Consumer Nutrigenetics Testing: An Overview
por: Floris, Matteo, et al.
Publicado: (2020)

An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation
por: Chaloupka, Frank J, et al.
Publicado: (2015)

Public Perceptions of Breast Implant Complications and the FDA Boxed Warning on Implants
por: Hyland, Colby J., et al.
Publicado: (2022)

Direct-to-Consumer Genetic Testing in Korea: Current Status and Significance in Clinical Nutrition
por: Lee, Ga Young, et al.
Publicado: (2021)

Genetic testing—whether to allow complete freedom? Direct to consumer tests versus genetic tests for medical purposes
por: Malgorzata, Madej, et al.
Publicado: (2021)

The past, present, and future of direct-to-consumer genetic tests
por: Helgason, Agnar, et al.
Publicado: (2010)

Direct-to-consumer genetic tests: beyond medical regulation?
por: Magnus, David, et al.
Publicado: (2009)

Direct-to-Consumer Genetic Testing: A Comprehensive View
por: Su, Pascal
Publicado: (2013)

Ethical Issues Associated With Direct-to-Consumer Genetic Testing
por: Panacer, Kirpal S
Publicado: (2023)

Health care providers and direct-to-consumer access and advertising of genetic testing in the United States
por: Myers, Melanie F
Publicado: (2011)

Updating the landscape of direct-to-consumer pharmacogenomic testing
por: Filipski, Kelly K, et al.
Publicado: (2017)

Physician Experience with Direct-To-Consumer Genetic Testing in Kaiser Permanente
por: Jonas, M. Cabell, et al.
Publicado: (2019)

Autobiologies on YouTube: Narratives of Direct-to-Consumer Genetic Testing
por: Harris, Anna, et al.
Publicado: (2014)

The sense and nonsense of direct-to-consumer genetic testing for cardiovascular disease
por: Janssens, A. C. J. W., et al.
Publicado: (2011)

Sperm donor attitudes and experiences with direct-to-consumer genetic testing
por: Wodoslawsky, Sascha, et al.
Publicado: (2023)

Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs
por: Ahuja, Vishal, et al.
Publicado: (2015)

1863. Antibiotic Prescribing Before and After an FDA Boxed Warning on Fluoroquinolones in 2016
por: Willis, Zachary, et al.
Publicado: (2018)

Assessing provider and racial/ethnic variation in response to the FDA antidepressant box warning
por: Cook, Benjamin L., et al.
Publicado: (2019)

Unicorn Poo and Blessed Waters: COVID-19 Quackery and FDA Warning Letters
por: Bramstedt, Katrina A.
Publicado: (2020)

Consumers report lower confidence in their genetics knowledge following direct-to-consumer personal genomic testing
por: Carere, Deanna Alexis, et al.
Publicado: (2015)

No two classes of biosimilars: Urgent advice to the US Congress and the FDA
por: Niazi, Sarfaraz K.
Publicado: (2022)

Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022
por: Dmour, Isra
Publicado: (2022)

Preconceptional genetic carrier testing and the commercial offer directly-to-consumers
por: Borry, Pascal, et al.
Publicado: (2011)

Why not order direct-to-consumer genetic testing for your children?
por: Bunnik, Eline M
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_qspueop6oftpiditelf6rn0tft